Neuralstem Inc (CUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Neuralstem Inc (CUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH58466D
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Neuralstem Inc (Neuralstem) is a biopharmaceutical company that develops novel treatments for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke, spinal cord injury, multiple sclerosis, optic neuritis, Alzheimer's disease, traumatic brain injury, peripheral nerve injury, diabetic neuropathy, lysosomal disease, Parkinson's disease, huntington's disease and cerebral palsy, among others. It provides drug treatment for depressive disorder, cognitive complication due to diabetes, post traumatic stress disorder, neurodegeneration and anti aging. The company develops methods to generate replacement cells from neural stem cells. It conducts investigational and discovery research on proprietary neural stem cell lines, neurogenic small molecule screening platform, and neurogenic small molecule portfolio. Neuralstem is headquartered in Germantown, Maryland, the US.

Neuralstem Inc (CUR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Neuralstem Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Neuralstem Inc, Medical Devices Deals, 2012 to YTD 2018 9

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Neuralstem Inc, Pharmaceuticals & Healthcare, Deal Details 11

Equity Offering 11

Neuralstem Raises USD6 Million Public Offering of Shares and Warrants 11

Neuralstem Raises USD20 Million in Private Placement of Shares 13

Neuralstem Raises USD1.1 Million in Private Placement of Shares 14

Neuralstem Raises USD8 Million in Public Offering of Shares 15

Neuralstem Raises USD3.06 Million in Public Offering of Shares 17

Neuralstem Completes Private Placement Of Common Stock For USD 20 Million 18

Neuralstem Completes Private Placement Of Units For USD 4.6 Million 19

Neuralstem Completes Public Offering Of Shares For USD 7 Million 21

Neuralstem Completes Public Offering Of Common Stock For USD 2.8 Million 22

Neuralstem Completes Private Placement Of Common Stock For USD 5.2 Million 23

Neuralstem Inc-Key Competitors 25

Neuralstem Inc-Key Employees 26

Neuralstem Inc-Locations And Subsidiaries 27

Head Office 27

Recent Developments 28

Financial Announcements 28

Aug 15, 2018: Neuralstem provides business update and reports second quarter 2018 fiscal results 28

May 15, 2018: Neuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results 31

Apr 02, 2018: Neuralstem Reports Year End 2017 Fiscal Results and Business Update 33

Nov 13, 2017: Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update 35

Aug 08, 2017: Neuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business Update 37

May 10, 2017: Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update 39

Mar 23, 2017: Neuralstem Reports Year End 2016 Fiscal Results and Business Update 41

Corporate Communications 43

Aug 06, 2018: Neuralstem appoints Jim Scully as interim chief executive officer 43

Dec 20, 2017: New Member appointed to the Board of Directors of Neuralstem 44

Nov 08, 2017: Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer 45

Sep 25, 2017: Neuralstem Announces the Appointment of Two New Members to the Board of Directors 46

Legal and Regulatory 47

Jun 26, 2017: Neuralstem added to the Russell Microcap Index 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48

List of Figures

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Neuralstem Inc, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Neuralstem Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Neuralstem Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Neuralstem Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Neuralstem Inc, Medical Devices Deals, 2012 to YTD 2018 9

Neuralstem Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Neuralstem Raises USD6 Million Public Offering of Shares and Warrants 11

Neuralstem Raises USD20 Million in Private Placement of Shares 13

Neuralstem Raises USD1.1 Million in Private Placement of Shares 14

Neuralstem Raises USD8 Million in Public Offering of Shares 15

Neuralstem Raises USD3.06 Million in Public Offering of Shares 17

Neuralstem Completes Private Placement Of Common Stock For USD 20 Million 18

Neuralstem Completes Private Placement Of Units For USD 4.6 Million 19

Neuralstem Completes Public Offering Of Shares For USD 7 Million 21

Neuralstem Completes Public Offering Of Common Stock For USD 2.8 Million 22

Neuralstem Completes Private Placement Of Common Stock For USD 5.2 Million 23

Neuralstem Inc, Key Competitors 25

Neuralstem Inc, Key Employees 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Neuralstem Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17835
Site License
USD 500 INR 35670
Corporate User License
USD 750 INR 53505

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com